Abstract:Recombinant human erythropoietin produced by mammalian cells contains about 40% carbohydrates which maintain its stability and long residence in body. However, mammalian derived Epo has low yields and high costs of production. In this article, a cost-effective strategy of producing non-glycosylated Epo from Escherichia coli and then PEGylating it to replace the role of sugar chains was investigated. Recombinant human non-glycosylated erythropoietin (rh-ngEpo) was overexpressed as inclusion body in E. coli. As the routine inclusion body washing step resulted in poor protein recovery and purity, a new process scheme of using strong ion-exchange chromatography to purify denatured rh-ngEpo from inclusion body before refolding was developed. The purity of the denatured rh-ngEpo was increased from 59% to over 90%. Rh-ngEpo was then refolded and subsequently purified by one step of weak cation-exchange chromatography to 98% pure. Final protein yield was 129 mg/l, a significant improvement from 49 mg/l obtained via the conventional practice. The in vitro bioactivity of purified rh-ngEpo was comparable with the CHO-expressed Epo and the formation of native secondary structure was also confirmed by CD spectra. Rh-ngEpo was then modified by a 20 kDa methoxy polyethylene glycol (PEG) succinimidyl carbonate. The monoPEGylated protein, which retained 68% bioactivity, had enhanced thermal stability and a remarkably prolonged circulating half-life in rats as compared with that of the unmodified protein. These studies demonstrated the feasibility of PEGylating rh-ngEpo as a promising way for the development of new Epo drugs.

Preparation and PEGylation of exendin-4 peptide secreted from yeast Pichia pastoris.

Screening and Identification of A Targeting Peptide to Nglp-1r from Phage Display Peptide Library

Preparation and Characterization of A Novel Exendin-4 Human Serum Albumin Fusion Protein Expressed in Pichia Pastoris

Expression of an Endo-Β-1,4-glucanase Gene from Orpinomyces PC-2 in Pichia Pastoris.

Site-specific N-terminal PEGylation-based controlled release of biotherapeutics: An application for GLP-1 delivery to improve pharmacokinetics and prolong hypoglycemic effects

The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo

One-Step Purification of a Fusion Protein of Glucagon-Like Peptide-1 and Human Serum Albumin Expressed in Pichia pastoris by an Immunomagnetic Separation Technique

High cell density cultivation of recombinant Escherichia coli for prodrug of recombinant human GLPs production

Recent Development of Exendin-4 and Its Analogs

The construction of long-acting exendin-4 analog and its hypoglycemic effect in diabetic mice

Expression of Human Globular Adiponectin-Glucagon-like Peptide-1 Analog Fusion Protein and Its Assay of Glucose-Lowering Effect in Vivo.

Exendin 4-Hapten Conjugate Capable of Binding with Endogenous Antibodies for Peptide Half-life Extension and Exerting Long-Acting Hypoglycemic Activity

Synthesis and purification of mono-PEGylated insulin.

In vitro cellular uptake and insulin secretion studies on INS-1E cells of exendin-4-loaded self-nanoemulsifying drug delivery systems

In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel.

Stability of Synthetic Exendin-4 in Human Plasma in Vitro

Separation and Purification of Recombinant Human Insulin and C Peptide Expressed in the Yeast Pichia Pastoris

Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris

Engineering of a Biologically Active Glycosylated Glucagon-Like Peptide-1 Analogue

Efficient preparation and PEGylation of recombinant human non-glycosylated erythropoietin expressed as inclusion body in E. coli

A pH‐Triggered Self‐Unpacking Capsule Containing Zwitterionic Hydrogel‐Coated MOF Nanoparticles for Efficient Oral Exendin‐4 Delivery